Sanofi buying Blueprint Medicines for up to $9.5 billion
Sanofi agreed to acquire Blueprint Medicines, a Cambridge, Mass.-based biotech focused on rare immunology diseases, for $9.1 billion in cash and up to $400 million in earnouts.
Why it matters: This is Sanofi's third big buy in 2025, following Dren Bo and Vigil Neuroscience, as it tries to build up a portfolio that's become too reliant on its Dupixent anti-inflammatory drug.
The situation that's been exacerbated by some recent clinical setbacks and the April sale of a control stake in its consumer health unit to Clayton Dubilier & Rice for €10 billion.
By the numbers: Blueprint stockholders are slated to receive $129 per share at closing, representing a 23.3% premium over Friday's closing price.
They'd also get contingent value rights that could include up to $6 in milestone payments.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Sanofi (SNY) Takes Bold $9.5Bn Immunology Leap
Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant's fourth major strategic acquisition this year, but this deal stands out. Sanofi isn't just picking up a drug or two; it's gaining access to a robust immunology pipeline of internally developed therapies. In addition to securing Ayvakit, a treatment for systemic mastocytosis, the acquisition reinforces Sanofi's shift toward high-value biopharma assets. Despite recent stock underperformance, this bold move strengthens my long-term bullish outlook on Sanofi. Confident Investing Starts Here: Sanofi's Strategic Pivot Towards High-Value Biopharma Sanofi's recent sale of Opella, its consumer healthcare division, highlights a broader strategic shift toward prioritizing high-margin biopharma operations. The company has seen major success with Dupixent—a blockbuster drug for inflammatory conditions like COPD and dermatitis, which generated over $13 billion in sales last year and now makes up nearly 30% of Sanofi's total revenue. This move underscores Sanofi's commitment to doubling down on its most profitable and innovative drug assets. Immediate Ayvakit Revenue Sanofi's acquisition of Blueprint, while a sizable investment, brings immediate benefits in both revenue diversification and pipeline strength. Ayvakit, approved for treating advanced systemic mastocytosis (AdvSM) in 2021 and indolent systemic mastocytosis (ISM) in 2023, addresses a rare disease with few treatment options. The drug generated $479 million in 2024, and Blueprint projected up to $720 million in revenue for 2025. With peak annual sales expected to reach around $2 billion before 2030, Ayvakit offers Sanofi a strong, near-term revenue driver, helping to de-risk the $9.1 billion upfront cost. Strategically, it's also a seamless addition to Sanofi's growing immunology portfolio. Boosting Sanofi's Immunology Future with Blueprint's Pipeline While Blueprint's pipeline includes several candidates, the spotlight is on two key assets: elenestinib and BLU-808. Elenestinib is a next-generation KIT D816V inhibitor currently in late-stage development for systemic mastocytosis (SM). It aims to improve upon the safety profile of Ayvakit, potentially appealing to patients who may avoid Ayvakit due to side effects such as fatigue and cognitive impairment, thereby expanding Sanofi's market share in SM. BLU-808, on the other hand, is an early-stage asset targeting a broader range of inflammatory conditions, including allergic asthma and allergic rhinoconjunctivitis. Unlike SM, these are far more prevalent diseases, offering significantly larger commercial opportunities. Importantly, BLU-808 is tied to two contingent value rights (CVRs), which are dependent on achieving specific development and regulatory milestones. These CVRs provide a layer of downside protection for Sanofi—if BLU-808 fails in clinical trials, the company's overall payout for the asset is reduced. Navigating Margin Pressures with Strategic Investment All of this comes against the backdrop of ongoing margin pressures for Sanofi. The company has already walked back its 2025 operating margin target of 32%, citing pricing pressures in its legacy general medicines segment and a ramp-up in R&D spending. While Sanofi remains active in diabetes with drugs like Lantus and Toujeo, these products now face significant pricing headwinds from generics, making them far less profitable than they once were. The Blueprint acquisition underscores Sanofi's renewed focus on innovation and high-margin biopharma assets. Though this pivot comes at the cost of near-term margin dilution, it reflects a longer-term strategy: investing in R&D today in hopes of developing the next wave of blockbuster therapies. In this context, Sanofi is clearly still in the midst of a strategic transformation—one currently anchored by the strong performance of Dupixent. Unlike previous 'bolt-on' deals that added just a drug or two, the Blueprint acquisition marks a more decisive step toward reshaping Sanofi's portfolio around premium, next-generation therapeutics. What is the Price Prediction for SNY Stock? On Wall Street, SNY sports a consensus Moderate Buy rating based on two Buy, three Hold, and zero Sell ratings in the past three months. Sanofi's average stock price target of $62.20 implies ~25% upside potential over the next 12 months. Last week, analyst Sachin Jain from Bank of America Securities maintained a Buy rating on SNY. The analyst was bullish on Sanofi's pipeline, particularly itepekimab, despite it failing in one of two Phase 3 trials for COPD. Moreover, he noted that 'Sanofi's low price-to-earnings ratio, reflecting limited pipeline upside, is seen as an opportunity given the promising data from these trials, indicating a potential R&D turnaround for the company.' Blueprint Deal Seals the Verdict on SNY In summary, Sanofi's acquisition of Blueprint offers both near-term revenue and long-term growth potential. Ayvakit serves as a valuable bolt-on asset, while pipeline candidates like elenestinib and BLU-808 significantly enhance Sanofi's immunology portfolio. More importantly, the deal reflects Sanofi's strategic pivot toward higher-margin biopharma assets at a time when older drugs like Lantus are facing profitability headwinds. Though the investment may pressure margins in the short run, it sets the stage for long-term growth in a high-value segment of the pharmaceutical market. Notably, the deal is expected to be EPS accretive by 2027, thanks to Ayvakit's revenue potential, which will help justify and offset a large portion of the upfront $9.5 billion cost. Overall, Sanofi has secured a promising set of assets at a reasonable valuation while extending its leadership in immunology beyond Dupixent. With a modest P/E ratio of 20.5 and a solid 3.27% dividend yield, SNY stands out as a compelling long-term investment opportunity for investors seeking to tap into the expanding biopharmaceutical space.
Yahoo
14 hours ago
- Yahoo
‘Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033
The global atopic dermatitis (AD) market is poised to reach $22.4bn in drug sales within the decade, buoyed by the availability of targeted therapies, market analysis suggests. A 2025 report published by GlobalData, which analysed the seven major markets of the US, UK, France, Germany, Italy, Spain, and Japan, forecasts sector sales will reach the $22.4bn figure by 2033, up from $8.5bn in 2023, reflecting a compound annual growth rate (CAGR) of 10.2%. While not as fast-growing as the weight loss market in the metabolic disease space, the AD market growth is salient given the market's size compared to other dermatology indications. GlobalData healthcare analyst, Filippos Maniatis, comments: 'AD is a growing market with an impressive pipeline of new products from current and future players in the field. The AD space was previously dominated by broad-acting immunomodulatory agents, which are now being slowly replaced by more targeted agents. This shift is likely due to better comprehension of the pathophysiology behind AD and the approval of several new systemic agents.' GlobalData is the parent company of Pharmaceutical Technology. One of those targeted agents that has taken the market by storm is Regeneron and Sanofi's jointly developed Dupixent (dupilumab), first approved in the US in 2017. The blockbuster monoclonal antibody has seen its sales increase year-over-year amid high uptake from AD – reaching $14.9bn in sales in 2024. Dupixent is approved for a range of diseases, including a lucrative asthma indication. The report says that the gap of unmet need in AD, which is closing courtesy of Sanofi and Regeneron, is set to shrink even further depending on future approvals for more targeted therapies. One modality poised as a future disruptor is the OX40 inhibitor class of drugs that work by inhibiting T-cell activation and inflammation via the OX40 receptor on the immune cells. Pipeline candidates in development include Amgen and Kyowa Kirin's rocatinlimab, Sanofi's amlitelimab, and Astria Therapeutics' telazrolimab. Another class with a potential future in AD is interleukin (IL) inhibitors. LEO Pharma, GSK, and Nektar all have assets in clinical development. Maniatis concludes: 'With multiple pipeline agents in development, key unmet needs may be further addressed. Such unmet needs include the lack of personalised treatments through improved diagnostic methods, the high cost of current therapy options, the limited therapeutic options for chronic hand eczema, and better long-term disease control and management.' "'Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
a day ago
- Yahoo
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries. Now in its 11th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company's growth and results. In 2024 alone, more than 32,000 Sanofi employees - 40% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.55%1 of its capital. Chief Executive Officer of Sanofi"The Board of Directors and I are particularly proud to see the growing participation of our employees in our global employee shareholder plan, a commitment that has endured for more than a decade. This renewed confidence illustrates their active support for our transformation into a leading biopharmaceutical company at a decisive moment in our history.' From June 10th, 2025, employees will be offered shares at a subscription price of €72.97, which is equal to a 20% discount on the average of the 20 opening prices of Sanofi shares from May 7 to June 3, 2025. For every five shares subscribed, employees will be offered one free matching share (up to a maximum of four matching shares per employee). Every eligible employee may purchase up to 1,500 Sanofi shares within the legal limit (maximum payment amount may not exceed 25% of their gross annual salary, minus any voluntary contributions already made in employee savings schemes, such as Company Savings Plan and/or Group Savings Plan and/or Group Retirement Savings Plan (PERCO) - voluntary contributions to the PERCOL are not concerned by this limit-during 20252. Detailed conditionsAn eligibility condition of three months employment by the closing date of the offer period will apply. Eligible staff will be able to subscribe for shares from June 10, 2025 (inclusive) to June 30, 2025 (inclusive). The issue is expected to be completed and the delivery of the securities carried out by the end of July number of shares offered is limited to 1% of Sanofi's share capital as of January 29, 2025, reduced by the impact of the capital increase reserved to employees carried out in July 2024 (i.e., 10,386,831 shares). The new shares, including the matching shares (the "Shares"), will be subscribed (or delivered) either directly or through the intermediary of employee mutual funds ("FCPE"), depending on the regulations and/or tax regime applicable in the various countries of residence of those eligible for the capital increase. The Shares will be fully fungible with the existing ordinary shares comprising the share capital of Sanofi and will acquire dividend rights as from January 1, voting rights attached to the subscribed Shares will be exercised directly by the employees. Shares and the corresponding FCPE units subscribed, in France, within the framework of the Sanofi Group savings plan (PEG) must be held for a period of approximately five years, i.e. until May 31, 2030, except upon the occurrence of an early release event provided for under Article R. 3324-22 of the French Labour Code. For shares subscribed outside of France within the framework of the Sanofi International Group Shareholding Plan (IGSP), this period could be shortened to three years, i.e. until May 31, 2028, depending on the legal and tax implications that may arise in the subscriber's country. Admission of the Shares to trading on the Euronext Paris market (ISIN Code: FR0000120578) on the same line as the existing shares will be requested as soon as possible after the completion of the capital press release does not constitute an offer to sell or a solicitation to buy Sanofi shares. The offer of Sanofi shares reserved for employees will only be made in countries where such an offer has been registered with or notified to the competent local authorities and/or following the approval of a prospectus by the competent local authorities, or in consideration of an exemption from the requirement to prepare a prospectus or to register or notify of the offer, where such procedure is generally, the offer will only be made in countries where all required registration and/or notification procedures have been carried out, approvals obtained, and procedures for consulting or informing employee representatives press release is not intended for and should not be copied to or distributed in countries where such a prospectus has not been approved or such exemption is not available or where all necessary registration, notification, consultation and/or information procedures have not been completed or authorisations obtained. This relates in particular to Japan, Morocco and the Philippines, where to date formalities are still pending with the authorities but could also relate to other countries. This press release is prepared in accordance with the exemption from publication of a prospectus under Article 1 4°i) and 5°h) of the Prospectus Regulation (EU) 2017/1129. It constitutes the document required to meet the conditions for exemption from publication of a prospectus as defined by the Prospectus Regulation. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Media RelationsSandrine Guendoul | + 33 6 25 09 14 25 | Léa Ubaldi | + 33 6 30 19 66 46 | Léo Le Bourhis | + 33 6 75 06 43 81| Rouault | + 33 6 70 93 71 40 | Berland | +1 215 432 0234 | Gilbert | + 1 516 521 2929 | Investor RelationsThomas Kudsk Larsen |+ 44 7545 513 693 | Kaisserian | + 33 6 47 04 12 11 | Lauscher | + 1 908 612 7239 | Browne | + 1 781 249 1766 | Pham | + 33 7 85 93 30 17 | Elgoutni | + 1 617 710 3587 | Châtelet | + 33 6 80 80 89 90 | Yun Li | + 33 6 84 00 90 72 | Shares held by the employees according to article L.225-102 of the French Commercial Code 2 For employees subscribing under the PEG: The allocation of all or part of the amount of profit-sharing arrangement (participation and or intéressement) and the transfer of available assets from the FCPE 'PEG Sanofi Monétaire' of the PEG must comply only with the limit of 1,500 shares. Attachment Press releaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
